Mounjaro® (Tirzepatide) Injection – Once Weekly

Mounjaro® (Tirzepatide) Injection – Once Weekly

Dual GIP/GLP-1 Receptor Agonist for Type 2 Diabetes & Weight Management

Mounjaro® is a once-weekly injectable medication that contains tirzepatide, the first-in-class dual GIP and GLP-1 receptor agonist. It is approved to help improve blood sugar control in adults with type 2 diabetes and is widely prescribed off-label for weight loss under medical supervision.

By mimicking two natural incretin hormones—GLP-1 and GIP—Mounjaro helps regulate insulin secretion, reduce appetite, slow gastric emptying, and promote significant weight loss.

✅ Key Benefits:

• Improves blood glucose control in type 2 diabetes

• Supports clinically significant weight loss

• Once-weekly injection – convenient and easy to use

• Shown to reduce HbA1c levels more effectively than GLP-1s alone

• Can be used alone or with other diabetes medications (e.g., metformin)

📦 Available Strengths (per dose):

• 2.5 mg (starter dose)

• 5 mg

• 7.5 mg

• 10 mg

• 12.5 mg

• 15 mg (maximum dose)

Each strength is supplied in prefilled pens, typically in a 4-pen pack (4-week supply).

💉 How to Use:

• Inject subcutaneously once weekly (same day each week)

• Administer in the abdomen, thigh, or upper arm

• Dose is typically started at 2.5 mg and increased gradually